NCI-H2030 Xenograft Model Service for NSCLC

The NCI-H2030 xenograft model captures one of the most genomically complex and clinically aggressive molecular subtypes of non-small cell lung cancer—the KLK signature characterized by concurrent KRAS, STK11/LKB1, and KEAP1 mutations superimposed on TP53 loss. Alfa Cytology delivers fully customizable NCI-H2030 xenograft services—from tumor establishment and longitudinal monitoring to multi-layered endpoint analysis—empowering researchers to dissect NRF2-driven antioxidant addiction, XPO1-dependent nuclear export vulnerabilities, and replication-stress liabilities in a quadruple-mutant tumor setting.

Overview of NCI-H2030 Xenograft Model for NSCLC

The NCI-H2030 cell line was established in September 1988 from a lymph-node metastatic lesion of a non-smoking male patient with lung adenocarcinoma. It exhibits epithelial morphology with adherent growth properties and has been authenticated through STR profiling. Genomically, NCI-H2030 belongs to the KLK molecular subtype of LUAD—defined by the co-occurrence of activating KRAS mutation, inactivating STK11/LKB1 alteration, and disruptive KEAP1 mutation—further complicated by concurrent TP53 loss. This quadruple-mutant constellation is present in a minority of NSCLC cases yet accounts for a disproportionate share of treatment-resistant, rapidly progressive disease. The line is maintained in RPMI 1640 supplemented with 10% fetal bovine serum and demonstrates reliable tumorigenicity in immunodeficient murine hosts, making it a reference model for one of the most challenging molecular subsets in thoracic oncology.

Fig 1. Darlifarnib (KO-2806) selectively inhibited farnesyltransferase (IC50 2.4 nM) over geranylgeranyltransferase, suppressed RHEB-mediated mTORC1 signaling and showed antitumor activity in HRAS-mutant xenografts — the pharmacological basis for resensitizing relapsing NCI-H2030 tumors to adagrasib. (Patel, Hetika Vora, et al., 2026)

Functionally, KEAP1 loss in NCI-H2030 unleashes constitutive NRF2-mediated antioxidant transcriptional programs, conferring redox resilience and metabolic plasticity that shield the tumor from oxidative and genotoxic stress. Concurrent STK11 deficiency amplifies replication stress through dysregulated cell-cycle checkpoint control, while TP53 inactivation removes the G1/S DNA-damage surveillance barrier—collectively creating a state of heightened genomic instability paradoxically coupled with robust survival signaling. Notably, NCI-H2030 exhibits elevated YAP1 transcriptional activity and has been identified as a prototype for XPO1-dependent nuclear export addiction, rendering it sensitive to selective inhibitor of nuclear export (SINE) compounds. These convergent vulnerabilities make the NCI-H2030 xenograft an essential platform for testing rational combination strategies that simultaneously target oncogenic drivers, redox homeostasis, and DNA-damage response pathways in a molecularly annotated, preclinical context.

Cell Line Information: NCI-H2030

The NCI-H2030 cell line (ATCC CRL-5914) was established from a lymph-node metastatic lesion of a non-smoking male with lung adenocarcinoma. The line displays epithelial morphology with adherent growth characteristics and has been authenticated by STR profiling. It is maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37°C under 5% CO₂. The table below summarizes its key biological and molecular attributes.

Our Services

Alfa Cytology brings unparalleled expertise in KLK-subtype NSCLC modeling to every NCI-H2030 xenograft engagement. Our capabilities extend well beyond standard tumor volume readouts—we deliver integrated multi-omic endpoint characterization encompassing NRF2 transcriptional profiling, YAP1 nuclear-cytoplasmic localization analysis, replication-stress marker quantification, and XPO1 cargo-export assessment directly from xenograft tissue. Whether your program targets the KRAS oncogene, exploits NRF2-driven redox addiction, disrupts XPO1-mediated nuclear export, or leverages replication-stress vulnerabilities with ATR inhibitors, our team architects studies that yield mechanistically grounded, decision-enabling data in one of the most genomically complex NSCLC backgrounds.

Workflow of NCI-H2030 Xenograft Model Construction

Establishing a reproducible NCI-H2030 xenograft model requires meticulous attention to the aggressive proliferative kinetics and redox-protected phenotype inherent to the KLK molecular subtype. At Alfa Cytology, each study is conducted under IACUC-approved protocols with stringent quality controls to ensure tumor take consistency and preserve the quadruple-mutant genotype throughout the study duration. The operational workflow proceeds as follows:

1. Cell Line Expansion and Pre-Implantation Validation: NCI-H2030 cells are expanded in RPMI 1640 with 10% FBS under standard conditions. Each batch undergoes mycoplasma PCR testing, STR authentication, and viability assessment. Given the line's aggressive growth properties, cultures are harvested during logarithmic phase to maximize engraftment efficiency and minimize necrotic burden at implantation.
2. Recipient Animal Selection and Acclimation: Immunodeficient mice (BALB/c nude or NOD/SCID) are health-screened and acclimated for a minimum of five days. Baseline body weights and clinical observations are documented to ensure cohort uniformity prior to tumor cell inoculation.
3. Subcutaneous Tumor Cell Implantation: A single-cell suspension (1 × 10⁶ to 5 × 10⁶ cells in 100–200 µL of serum-free medium, optionally mixed 1:1 with Matrigel™) is injected subcutaneously into the flank under aseptic technique. Tumors typically become palpable within 7–12 days post-implantation.
4. Tumor Monitoring and Cohort Randomization: Tumor dimensions are measured by digital caliper every 2–3 days, with volumes calculated using the modified ellipsoid formula (length × width² / 2). Upon reaching the target volume (typically 100–150 mm³), animals are randomized into vehicle-control and treatment groups using stratified randomization based on tumor size and body weight.
5. Therapeutic Administration and Clinical Surveillance: Test compounds are administered according to sponsor-defined protocols (route, frequency, and duration). Mice are evaluated daily for body weight, clinical signs, and treatment-related adverse events, with strict enforcement of predefined humane endpoints.
6. Terminal Harvest and Multi-Modal Endpoint Analysis: At study termination, tumors are excised, weighed, photographed, and allocated for comprehensive analysis: histopathology (H&E, Ki-67, TUNEL), NRF2-pathway profiling (NRF2, NQO1, HO-1 by IHC or Western blot), YAP1 localization and transcriptional activity assessment, replication-stress markers (γH2AX, p-CHK1, p-ATR), and pharmacokinetic correlation. All data are synthesized into a detailed study report with statistical evaluation.

Fig 1. In vitro characterisation of theRM-1 cell lines edited for mCAIX expression. (Kalniņa Z, et al., 2025)

Case Study-NCI-H2030 Xenograft Model Development

In a preclinical program targeting the KLK molecular subtype of NSCLC, Alfa Cytology established subcutaneous NCI-H2030 xenografts to evaluate the antitumor efficacy of a KRAS G12C inhibitor in combination with an mTORC1/2 dual inhibitor, a regimen designed to simultaneously suppress oncogenic signaling and disrupt the metabolic plasticity conferred by concurrent STK11 and KEAP1 loss. Following tumor engraftment and randomization, animals received daily oral dosing of the KRAS inhibitor plus intermittent administration of the mTOR inhibitor over a four-week treatment window. Longitudinal caliper measurements demonstrated significant tumor growth inhibition in the combination arm compared to either monotherapy or vehicle control. Terminal pharmacodynamic analysis revealed marked suppression of intratumoral p-S6 and p-4E-BP1 in combination-treated tumors, alongside attenuated NRF2-driven NQO1 expression. Body-weight trajectories remained stable across all cohorts, and no unexpected toxicological findings were observed in major organs. These findings illustrate the translational utility of the NCI-H2030 platform for validating rational polytherapy strategies that co-target oncogenic drivers and metabolic dependencies in quadruple-mutant NSCLC.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H2030 xenograft program provides access to a CRO with specialized expertise in quadruple-mutant, KLK-subtype tumor biology and the convergent vulnerabilities that define this aggressive molecular landscape. Our defining capabilities include:

• Authenticated NCI-H2030 master and working cell banks with documented STR profiles, mycoplasma-negative certification, and passage-controlled expansion preserving the KRAS/STK11/KEAP1/TP53 quadruple-mutant genotype.
• Specialized proficiency in KLK-subtype NSCLC pharmacology, encompassing KRAS-directed agents, NRF2-pathway disruptors, XPO1-targeted compounds, and ATR inhibitors tailored to replication-stress phenotypes.
• Integrated multi-omic endpoint analysis from xenograft tissue—including NRF2 transcriptional profiling, YAP1 nuclear-cytoplasmic localization, γH2AX replication-stress quantification, and mTOR-axis phospho-protein assessment—delivering mechanistic depth beyond standard efficacy metrics.
• Adaptive study designs supporting monotherapy, combination, dose-escalation, and acquired-resistance protocols with flexible cohort sizing and scheduling aligned to your translational objectives.
• Full regulatory compliance through IACUC oversight, GLP-aligned data capture, and comprehensive quality-assurance documentation suitable for IND-enabling submission packages.
• Expedited study initiation leveraging established NCI-H2030 tumor colonies, enabling randomization and first dosing to commence within days of project authorization.

Contact Us

Looking to tackle one of the most challenging molecular subtypes in NSCLC with a validated, quadruple-mutant xenograft model? We invite you to reach out to Alfa Cytology to explore how our NCI-H2030 platform can accelerate your drug-discovery program. Our scientific team will collaborate with you to design a tailored study protocol, select the most informative NRF2, YAP1, and replication-stress endpoints, and deliver robust efficacy data that supports your next critical decision. Contact us today to initiate your NCI-H2030 xenograft study and advance toward clinical translation.

For research use only. Not intended for any clinical use.